Literature DB >> 15315473

Common pathways of depression and pain.

Pedro L Delgado1.   

Abstract

Depressive disorders are chronic conditions that produce both emotional and physical symptoms. Increasing evidence suggests that in some patients with depressive disorders a neurodegenerative process may occur, highlighting the importance of early and aggressive intervention. Serotonin (5-HT) and norepinephrine (NE) neurotransmitter systems influence neuroplasticity in the brain, and both are involved in mediating the therapeutic effects of most currently available antidepressants. Some dual-action antidepressants have been shown to be effective in managing the pain symptoms associated with depression. These agents may have advantages over others by treating a wider array of physical symptoms. Additionally, these agents may also have a role in modulating neurogenesis and other neuroplastic changes, thereby leading to more complete recovery in patients suffering from the emotional and physical symptoms of chronic depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315473

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  33 in total

Review 1.  Emotion and pain: a functional cerebral systems integration.

Authors:  Gina A Mollet; David W Harrison
Journal:  Neuropsychol Rev       Date:  2006-09-28       Impact factor: 7.444

2.  The effect of sympathetic antagonists on the antidepressant action of alprazolam.

Authors:  Ra Al-Tubuly; Sm Aburawi; Ea Alghzewi; Zm Gorash; S Errwami
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

3.  Duloxetine for childhood depression with pain and dissociative symptoms.

Authors:  Pushpal Desarkar; Anindya Das; Vinod K Sinha
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-05-26       Impact factor: 4.785

4.  The impact of pain and other symptoms on quality of life in women with relapsing-remitting multiple sclerosis.

Authors:  Pamela K Newland; Robert T Naismith; Margaret Ullione
Journal:  J Neurosci Nurs       Date:  2009-12       Impact factor: 1.230

5.  Ceftriaxone inhibits stress-induced bladder hyperalgesia and alters cerebral micturition and nociceptive circuits in the rat: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome research network study.

Authors:  Daniel P Holschneider; Zhuo Wang; Huiyi Chang; Rong Zhang; Yunliang Gao; Yumei Guo; Jackie Mao; Larissa V Rodriguez
Journal:  Neurourol Urodyn       Date:  2020-06-23       Impact factor: 2.696

Review 6.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

7.  The Analgesic and Anxiolytic Effect of Souvenaid, a Novel Nutraceutical, Is Mediated by Alox15 Activity in the Prefrontal Cortex.

Authors:  Suku-Maran Shalini; Deron R Herr; Wei-Yi Ong
Journal:  Mol Neurobiol       Date:  2016-10-01       Impact factor: 5.590

8.  YL-0919, a dual 5-HT1A partial agonist and SSRI, produces antidepressant- and anxiolytic-like effects in rats subjected to chronic unpredictable stress.

Authors:  Yu-Hua Ran; Xiao-Xu Hu; Yu-Lu Wang; Nan Zhao; Li-Ming Zhang; Hua-Xia Liu; Yun-Feng Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

9.  Dopamine D3 receptor Ser9Gly and catechol-o-methyltransferase Val158Met polymorphisms and acute pain in sickle cell disease.

Authors:  Ellie Jhun; Ying He; Yingwei Yao; Robert E Molokie; Diana J Wilkie; Zaijie Jim Wang
Journal:  Anesth Analg       Date:  2014-11       Impact factor: 5.108

10.  17α-ethinyl estradiol attenuates depressive-like behavior through GABAA receptor activation/nitrergic pathway blockade in ovariectomized mice.

Authors:  Seyed Soheil Saeedi Saravi; Alireza Arefidoust; Rahele Yaftian; Seyed Sobhan Saeedi Saravi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2016-02-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.